ABVD is named as an intervention in 2 current clinical trials in our India, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland and Portugal registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia (1). The most-studied condition is Hodgkin Lymphoma, Adult.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
NCT04638790 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma, Adult
|
Phase 3 | Recruiting | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | India |
|
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00005584 · ClinicalTrials.gov ↗ · Lymphoma
|
Phase 3 | Active, closed | European Organisation for Research and Treatment of Cancer - EORTC | France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Portugal |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our India, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland and Portugal registers name ABVD as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia (1) and European Organisation for Research and Treatment of Cancer - EORTC (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ABVD works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ABVD works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ABVD (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.